Akter, A., & Alam, M. (2022). Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis. Brac University.
Chicago-viite (17. p.)Akter, Anika, ja Marzia Alam. Pharmacokinetics, Safety, Efficacy and Immunogenicity of Adalimumab Biosimilar ABP-501in Rheumatoid Arthritis and Plaque Psoriasis. Brac University, 2022.
MLA-viite (8. p.)Akter, Anika, ja Marzia Alam. Pharmacokinetics, Safety, Efficacy and Immunogenicity of Adalimumab Biosimilar ABP-501in Rheumatoid Arthritis and Plaque Psoriasis. Brac University, 2022.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.